Shares shifted sharply higher as Solid Biosciences delivered a one-two punch: a smaller-than-expected quarterly loss and reassuring safety data for its lead Duchenne muscular dystrophy gene therapy. The stock surged 13.1% to $9.49, its best showing in months — yet still sits roughly 45% below the average analyst price target, raising the question of whether this rally has real legs or just reflects short-term relief.
• The Loss Was Smaller, But It's Still a Loss
Solid reported Q2 EPS of -$0.38, beating the consensus estimate of -$0.46. The company generates zero revenue — trailing 12-month revenue is null — so the beat came entirely from tighter spending. For a biotech burning cash on clinical trials, controlling costs is the only lever management can pull while waiting for approval. Every dollar saved extends the runway, and that matters when you have no product on the market.
• 53 Patients Treated Without Major Safety Scares
The gene therapy has been well tolerated in the 53 participants dosed in the Phase 1/2 trial as of August 4, 2026, and the Phase 3 trial commenced dosing in Q2. Crucially, there have been no observed cases of drug-induced liver injury, myocarditis, or other severe immune complications. That's significant because rival Sarepta's approved therapy Elevidys was hit with a boxed warning after two fatal cases of acute liver failure. Solid's clean safety record with a simpler steroid-only immune management approach could become a key competitive differentiator.
• Cash Lasts Through Mid-2028, But the Clock Is Ticking
The company held $377.7 million in cash and securities, anticipated to fund operations into mid-2028. That gives Solid roughly two years to hit critical milestones — including a planned late Q4 2026 FDA meeting to seek guidance on accelerated approval. If that discussion goes poorly or the Phase 3 trial stalls, the company will likely need to raise more money, diluting current shareholders.
• Wall Street Is Bullish, But the Market Isn't Buying It Yet
Fourteen analysts give SLDB a consensus "Strong Buy" with an average target of $17.38 — nearly double today's price. Piper Sandler recently raised its target to $18. The disconnect reflects the inherent binary risk: if the therapy wins accelerated approval, the stock reprices dramatically upward; if trial data disappoints, the cash pile is all that cushions the fall.